MIT’s fabled billionaire scientist Robert Langer is stepping in to offer a key assist to Ovid CEO Jeremy Levin
Jeremy Levin’s biotech startup Ovid suffered a crippling blow late last year when the CEO was forced to concede that the critics were right all along and his lead drug was a bust in a late-stage test. But he’s gained an important assist in getting back up again and refocusing on other drugs in the pipeline.
Fabled MIT investigator and serial entrepreneur Robert Langer has signed on to chair the scientific board for Ovid, offering some guidance a day after Levin officially iced both programs for OV101. Ovid licensed out their second drug in the pipeline to Takeda, leaving a preclinical effort in place for a slate of drugs that includes OV882, a short hairpin RNA therapy targeting UBE3A gene expression in neurons.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.